Supply Chain Intelligence

Puma Biotechnology, Inc. Supply Chain

PBYI supply chain intelligence for Puma Biotechnology, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

PBYI ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

0Suppliers
5Customers
2Debt Items
20Related Chains

Puma Biotechnology, Inc. Suppliers

No suppliers on recordPuma Biotechnology, Inc. has not yet been matched to upstream suppliers in our database, or is still being processed.

Puma Biotechnology, Inc. Customers

TickerNameConfidenceEvidence
SIGNIFICANT-CUSTOMERS SIGNIFICANT-CUSTOMERS 92% We depend on a limited number of customers for a significant amount of our total revenue, and if we lose any of our significant customers, our business could be harmed.
SPECIALTY-PHARMACIES SPECIALTY-PHARMACIES 90% The Company sells NERLYNX to a limited number of specialty pharmacies and specialty distributors in the United States.
TKPHF Takeda Pharmaceutical Company Limited 72% tigational new drugs that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing appro…
TKPHF Takeda Pharmaceutical Company Limited 72% Reciprocal relationship from TKPHF graph: Reciprocal relationship from PBYI graph: Reciprocal relationship from TKPHF graph: Reciprocal relationship from PBYI graph: Reciprocal relationship from TKPH…
PRESENTATION-PUMA-BIOTECHNOLOGY-INC PRESENTATION-PUMA-BIOTECHNOLOGY-INC 62% unicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates. Estimate of certain variable consideration …

Puma Biotechnology, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
PBYI-DEBT-11677 Xbrl Convertible 90% xbrl convertible detail from xbrl 2013-12-31.
PBYI-DEBT Debt stack $16.0M 90% Market cache reports total debt of $16.0M.

Puma Biotechnology, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Puma Biotechnology, Inc..

Puma Biotechnology, Inc. Ownership

HolderNameConfidenceEvidence
PBYI-OWNER-ACORN-CAPITAL-ADVISORS-LLC ACORN CAPITAL ADVISORS, LLC 90% 13F overlay lists ACORN CAPITAL ADVISORS, LLC as top holder; 158 tracked holders.

Puma Biotechnology, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
CLYM Climb Bio, Inc. 100.00 2
DAWN Day One Biopharmaceuticals Inc 100.00 2
AXSM Axsome Therapeutics, Inc. 100.00 2
JBIO Jade Biosciences, Inc. 100.00 2
NBIX Neurocrine Biosciences, Inc. 100.00 2
NVAX Novavax, Inc. 100.00 2
MIRM Mirum Pharmaceuticals, Inc. 100.00 2
TAK Takeda Pharmaceutical Company Limited 100.00 2
JNJ Johnson & Johnson 100.00 2
KROS Keros Therapeutics, Inc. 100.00 2
NKTR Nektar Therapeutics 100.00 2
NTLA Intellia Therapeutics, Inc. 100.00 2
ZBIO Zenas BioPharma, Inc. 100.00 2
XLO Xilio Therapeutics, Inc. 100.00 2
CLLS Cellectis S.A. 100.00 2
GDTC CytoMed Therapeutics Limited 100.00 2
HOWL Werewolf Therapeutics, Inc. 100.00 2
INCY Incyte Corporation 100.00 2
DNLI Denali Therapeutics Inc. 100.00 2
HRTX Heron Therapeutics, Inc. 50.00 2
View PBYI supply chain intel →

Explore the full interactive supply chain map for Puma Biotechnology, Inc..

Open PBYI supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map